Navigation Links
Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round
Date:12/11/2009

OXFORD, England, December 11 /PRNewswire/ --

- Investment Follows Successful Phase Ii Clinical Results With cat Allergy T-cell Vaccine

- Funding to Progress ToleroMune(R) T-cell Allergy Vaccines Into Late-Stage Development

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has completed a GBP15 million ($25 million) fundraising. The investment round, which was led by Imperial Innovations and supported by existing shareholders including Invesco Perpetual and Lansdowne Partners, was significantly oversubscribed and is the company's third successful fundraising. The investment follows recently announced positive phase II results with Circassia's ToleroMune(R) cat allergy T-cell vaccine. The financing will support the acceleration of the programme into late-stage development and advance the clinical development of Circassia's broader portfolio of novel allergy T-cell vaccines.

"The success of this funding round is a great vote of confidence in Circassia's unique allergy T-cell vaccine technology and the dedication of our team," said Steve Harris, Circassia's CEO. "Our most recent clinical results clearly demonstrate the potential of our ToleroMune(R) technology, as well as scientifically validating our novel use of T-cell vaccines to improve the treatment of allergy sufferers. This new investment recognises the importance of these results, and represents a strategic milestone in the development of Circassia's next generation allergy treatments."

About Circassia's allergy T-cell vaccines

Circassia's range of allergy T-cell vaccines is based on its proprietary ToleroMune(R) technology. This technology utilises allergen epitopes to generate regulatory T cells that suppress allergic immune responses. Clinical results with Circassia's cat allergy T-cell vaccine show that short treatment regimes can greatly reduce patients' symptoms, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated. As a result, the company's allergy T-cell vaccines offer major potential clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potential regulatory and supply chain benefits. The short peptides utilised in Circassia's vaccines are manufactured chemically, in contrast to existing allergen immunotherapies, which are purified from natural sources. Circassia's approach applies the chemistry, manufacturing and control standards associated with conventional pharmaceuticals to its allergy T-cell vaccines. This fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and requiring elimination of the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments.

About Circassia

Circassia has a highly experienced management team with a proven track record in product development and commercialisation. Having successfully completed three fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Invesco Perpetual, Goldman Sachs and Lansdowne Partners.

    For more information please visit http://www.circassia.co.uk.

    Contacts
    Steve Harris Rob Budge
    CEO RJB Communications
    Circassia Tel: +44(0)1865-760969
    Tel: +44(0)1865-784574 Mobile: +44(0)7710-741241


SOURCE Circassia Ltd


'/>"/>
SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
2. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
3. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
4. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
5. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
6. Apnex Medical, Inc. Raises Additional $14 Million
7. Cambridge-based Ligon Discovery Raises $1M in Seed Funding
8. FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans
9. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
10. NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for Fiscal 2009
11. Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):